David Wells Increases Stake in Hims & Hers Health

David Wells, an insider at Hims & Hers Health, Inc. (NYSE: HIMS), purchased 3,656 shares of the company on June 11, 2026. This transaction reflects his growing interest in the healthcare platform, although the exact value of the trade wasn't disclosed.

Other Institutional Activity in Hims & Hers Health

BlackRock, Inc. trimmed its holdings by 236,346 shares, leaving it with 26,337,158 shares valued at approximately $546.8 million. Vanguard Portfolio Management LLC added a new position with 10,183,813 shares worth about $211.4 million. Similarly, Vanguard Capital Management LLC entered with 9,339,711 shares valued at around $193.9 million. Morgan Stanley significantly boosted its position by 4,959,856 shares, totaling 8,889,088 shares worth $184.5 million. Meanwhile, State Street Corp increased its stake by 154,498 shares, reaching a total of 7,460,023 shares valued at $154.9 million.

Hims & Hers Health Stock Snapshot

Shares of NYSE:HIMS recently traded near $26.82. The company boasts a market capitalization of approximately $6.21 billion and a forward P/E ratio of 30.13. With a beta of 2.398, the stock has seen a 52-week range between $13.74 and $70.43. Its 50-day moving average is $25.63, while the 200-day moving average is $33.57. The company maintains a current ratio of 1.689 and a quick ratio of 1.455, with a debt-to-equity ratio of 253.725.

Recent Earnings

Hims & Hers Health reported revenue of about $2.37 billion, reflecting a growth of 3.8%. Despite a net margin of -0.56%, the return on equity stands at -2.66%. The company is set to announce its next earnings on August 10, 2026.

Insider Buying and Selling at Hims & Hers Health, Inc.

In addition to David Wells' purchase, Christopher Payne bought 10,687 shares on June 15, 2026, while selling the same amount on the same day, without a planned strategy. Anja Manuel sold 10,040 shares, and Patrick Harrison Carroll, the Chief Medical Officer, sold 435 shares on June 15, 2026.

Analysts Set New Price Targets

On May 26, 2026, B of A Securities maintained a 'hold' rating with a $25 price target. Truist Securities also maintained a 'hold' rating with a target of $23 on May 22, 2026. JP Morgan initiated coverage with a 'buy' rating and a $35 target on April 24, 2026. The consensus among 14 analysts is to hold the stock, with an average price target of $26.61.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a healthcare platform connecting consumers with licensed professionals across the U.S., U.K., and several other countries. Based in San Francisco, it offers a wide range of health and wellness products and services, including personalized treatments for skincare, sexual health, and chronic conditions. The company is led by CEO Andrew Dudum and employs around 2,442 people.

Bottom Line

David Wells' purchase of Hims & Hers Health shares reflects continued insider interest in the company. Investors track these insider activities to gauge company sentiment, although 13F filings and insider trades are backward-looking and may not represent current positions. With a forward P/E ratio of 30.13 and a consensus 'hold' rating from analysts, Hims & Hers Health remains a company to watch in the healthcare sector.